Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05560399 · ClinicalTrials.gov registry record · Early Phase 1

A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

A Early Phase 1 study of Multiple Myeloma, sponsored by Icahn School of Medicine at Mount Sinai.

Active
Registry status
Early Phase 1
Development phase
7
Enrollment target
1
Study location

NCT05560399: Active Early Phase 1 study of Multiple Myeloma, sponsored by Icahn School of Medicine at Mount Sinai.

NCT05560399 is a Early Phase 1 study of Multiple Myeloma that is active but no longer recruiting, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 7 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05560399, a Early Phase 1 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Icahn School of Medicine at Mount Sinai.

ACTIVE NOT RECRUITING
Registry status
Early Phase 1
Development phase
7 participants
Enrollment target
1
Study location

Study Summary

This is a single-arm, open-label study evaluating the safety, tolerability and efficacy of Iberdomide (CC-220) in combination with Elotuzumab and Dexamethasone in patients with RRMM. The researchers hypothesize that the combination of Iberdomide and Elotuzumab will synergize to promote myeloma cell death, resulting in an overall response rate of at least 53%, with an acceptable safety profile. Patients will be enrolled in a 3+3 dose escalation cohort to evaluate the safety of this combination and to establish the MTD (maximum tolerated dose). The MTD will be the dose for the patients enrolled in dose expansion cohort. A total maximum of 37 patients will be recruited: maximum 18 patients will be recruited in the dose escalation phase, followed by an additional 19 patients in the dose expansion cohort for a total of 25 patients treated at the MTD.

Primary Outcome

The dose limiting toxicity (DLT) rate at the Maximum Tolerated Dose, defined as the proportion of patients in the safety population of the study that experience at least 1 DLT within the first cycle of Iberdomide (CC-220) in combination with Elotuzumab and Dexamethasone treated at the maximum tolerated dose (MTD).

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Dexamethasone
  • DRUG Iberdomide
  • DRUG Elotuzumab

Study Locations (1)

New York

  • Icahn School of Medicine - New York

Trial Details

FieldValue
Enrollment Target 7 participants
Start Date 2023-02-06
Est. Completion 2026-12
Phase Early Phase 1
Icahn School of Medicine at Mount Sinai

708 total trials

What the registry record for NCT05560399 still lists

NCT05560399 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Dexamethasone is the first listed.

NCT05560399 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT05560399 about?

NCT05560399 is a clinical study titled "A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma". This is a single-arm, open-label study evaluating the safety, tolerability and efficacy of Iberdomide (CC-220) in combination with Elotuzumab and Dexamethasone in patients with RRMM. The researchers hypothesize that the combination of Iberdomide and Elotuzumab will synergize to promote myeloma cell ...

What is the current status of trial NCT05560399?

This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 7 participants. The study started on 2023-02-06. Estimated completion is 2026-12.

What conditions does trial NCT05560399 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT05560399?

The interventions under investigation include: Dexamethasone (DRUG), Iberdomide (DRUG), Elotuzumab (DRUG).

Who is sponsoring clinical trial NCT05560399?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05560399 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05560399's enrollment target sits among peer trials

7 430th of 438 higher than 6 of 438 other Multiple Myeloma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05560399, the US trial registry maintained by the National Library of Medicine. NCT05560399 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.